718 related articles for article (PubMed ID: 33307033)
1. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.
Anstee QM; Lawitz EJ; Alkhouri N; Wong VW; Romero-Gomez M; Okanoue T; Trauner M; Kersey K; Li G; Han L; Jia C; Wang L; Chen G; Subramanian GM; Myers RP; Djedjos CS; Kohli A; Bzowej N; Younes Z; Sarin S; Shiffman ML; Harrison SA; Afdhal NH; Goodman Z; Younossi ZM
Hepatology; 2019 Nov; 70(5):1521-1530. PubMed ID: 31271665
[TBL] [Abstract][Full Text] [Related]
3. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
[TBL] [Abstract][Full Text] [Related]
4. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Younossi ZM; Stepanova M; Anstee QM; Lawitz EJ; Wai-Sun Wong V; Romero-Gomez M; Kersey K; Li G; Subramanian GM; Myers RP; Djedjos CS; Okanoue T; Trauner M; Goodman Z; Harrison SA
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2552-2560.e10. PubMed ID: 30779990
[TBL] [Abstract][Full Text] [Related]
5. The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression.
Younossi ZM; Stepanova M; Myers RP; Younossi I; Henry L
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):970-977.e1. PubMed ID: 35533993
[TBL] [Abstract][Full Text] [Related]
6. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib.
Younossi ZM; Stepanova M; Lawitz E; Charlton M; Loomba R; Myers RP; Subramanian M; McHutchison JG; Goodman Z
Liver Int; 2018 Oct; 38(10):1849-1859. PubMed ID: 29377462
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
[TBL] [Abstract][Full Text] [Related]
8. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
[TBL] [Abstract][Full Text] [Related]
9. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Loomba R; Noureddin M; Kowdley KV; Kohli A; Sheikh A; Neff G; Bhandari BR; Gunn N; Caldwell SH; Goodman Z; Wapinski I; Resnick M; Beck AH; Ding D; Jia C; Chuang JC; Huss RS; Chung C; Subramanian GM; Myers RP; Patel K; Borg BB; Ghalib R; Kabler H; Poulos J; Younes Z; Elkhashab M; Hassanein T; Iyer R; Ruane P; Shiffman ML; Strasser S; Wong VW; Alkhouri N;
Hepatology; 2021 Feb; 73(2):625-643. PubMed ID: 33169409
[TBL] [Abstract][Full Text] [Related]
10. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Aguilar Schall R; Jia C; McColgan B; Djedjos CS; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Muir AJ; Afdhal NH; Bosch J; Goodman Z
Hepatology; 2019 Dec; 70(6):1913-1927. PubMed ID: 30993748
[TBL] [Abstract][Full Text] [Related]
11. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Sanyal AJ; Anstee QM; Trauner M; Lawitz EJ; Abdelmalek MF; Ding D; Han L; Jia C; Huss RS; Chung C; Wong VW; Okanoue T; Romero-Gomez M; Muir AJ; Afdhal NH; Bosch J; Goodman Z; Harrison SA; Younossi ZM; Myers RP
Hepatology; 2022 May; 75(5):1235-1246. PubMed ID: 34662449
[TBL] [Abstract][Full Text] [Related]
12. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
[TBL] [Abstract][Full Text] [Related]
13. Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials.
Wong VW; Tak WY; Goh GBB; Cheng PN; Lawitz EJ; Younossi ZM; Vuppalanchi R; Younes Z; Alkhouri N; Wang L; Liu J; Kersey K; Myers RP; Harrison SA; Goodman Z; Trauner M; Romero-Gomez M; Anstee QM; Nguyen MH; Okanoue T
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):90-102.e6. PubMed ID: 35074532
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
15. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Loomba R; Lawitz E; Mantry PS; Jayakumar S; Caldwell SH; Arnold H; Diehl AM; Djedjos CS; Han L; Myers RP; Subramanian GM; McHutchison JG; Goodman ZD; Afdhal NH; Charlton MR;
Hepatology; 2018 Feb; 67(2):549-559. PubMed ID: 28892558
[TBL] [Abstract][Full Text] [Related]
16. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
[No Abstract] [Full Text] [Related]
17. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
[TBL] [Abstract][Full Text] [Related]
18. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
20. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.
Anstee QM; Neuschwander-Tetri BA; Wong VW; Abdelmalek MF; Younossi ZM; Yuan J; Pecoraro ML; Seyedkazemi S; Fischer L; Bedossa P; Goodman Z; Alkhouri N; Tacke F; Sanyal A
Contemp Clin Trials; 2020 Feb; 89():105922. PubMed ID: 31881392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]